[EN] CDK2 INHIBITORS AND METHODS OF USING THE SAME [FR] INHIBITEURS DE CDK2 ET LEURS PROCÉDÉS D'UTILISATION
摘要:
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
[EN] CDK2 INHIBITORS AND METHODS OF USING THE SAME [FR] INHIBITEURS DE CDK2 ET LEURS PROCÉDÉS D'UTILISATION
摘要:
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
[EN] TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE TETRAHYDRO-ISOQUINOLYL-ACETAMIDE DESTINES A SERVIR D'ANTAGONISTES DES RECEPTEURS D'OREXINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2004085403A1
公开(公告)日:2004-10-07
The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
申请人:Aissaoui Hamed
公开号:US20060178515A1
公开(公告)日:2006-08-10
The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
[EN] CDK2 INHIBITORS AND METHODS OF USING THE SAME<br/>[FR] INHIBITEURS DE CDK2 ET LEURS PROCÉDÉS D'UTILISATION
申请人:[en]CEDILLA THERAPEUTICS, INC.
公开号:WO2024026483A2
公开(公告)日:2024-02-01
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.